2023/09/22 17:35:06 | |
---|---|
Price | |
0.29 EUR | |
Difference | 1.05% (0.00) |
ISIN | BE0974281132 |
Symbol | - |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 27 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - (350) |
Ask (Ask size) | - (567,606) |
Open | 0.29 EUR |
High | 0.293 EUR |
Low | 0.287 EUR |
Close (prev. day) | 0.287 EUR |
VWAP | 0.290735 EUR |
Volume (pcs) | 112,228 |
Trading volume | 32,629.00 |
Number of trades | 72 |
Last size | 504 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/03 | Global Strategy 3Q 2024 | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/04/26 | Global Equity Ratings | ||
2024/03/26 | Global Strategy 2Q 2024 |
2023/09/22 17:35:06 | |
---|---|
Price | |
0.29 EUR | |
Difference | 1.05% (0.00) |
ISIN | BE0974281132 |
Symbol | - |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 27 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - (350) |
Ask (Ask size) | - (567,606) |
Open | 0.29 EUR |
High | 0.293 EUR |
Low | 0.287 EUR |
Close (prev. day) | 0.287 EUR |
VWAP | 0.290735 EUR |
Volume (pcs) | 112,228 |
Trading volume | 32,629.00 |
Number of trades | 72 |
Last size | 504 |
6m | 1Y | 3Y | |
Perf (%) | -52.38% | -67.08% | -92.64% |
Perf (abs.) | -0.32 | -0.59 | -3.65 |
Beta | 0.00 | -0.01 | 0.74 |
Volatility | 55.29 | 68.77 | 54.68 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.29 EUR (105,754) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.32 EUR (119,910) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.41 EUR (173,151) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.60 EUR (168,545) |
YTD High | date | 0.79 EUR (2023/04/14) |
YTD Low | date | 0.28 EUR (2023/09/19) |
52 Weeks High | date | 1.27 EUR (2022/10/19) |
52 Weeks Low | date | 0.28 EUR (2023/09/19) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2023/09/25 | 08:07 | 0.2595 EUR | 0.00 | 3 |
London Stock Exchange European Trade Reporting | 2023/09/25 | 17:30 | 0.299 EUR | 0.00 | 2 |
Frankfurt | 2023/09/25 | 08:08 | 0.2595 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2022/12/09 | 19:40 | 0.66 USD | 0.00 | 1 |
Euronext Brussels | 2023/09/22 | 17:35 | 0.29 EUR | 0.03 | 72 |
Duesseldorf | 2023/09/25 | 08:11 | 0.2585 EUR | 0.00 | 1 |
Berlin | 2023/09/25 | 08:22 | 0.2895 EUR | 0.00 | 1 |
BIOCARTIS GROUP NV |
- - |
Generaal de Wittelaan 11B - 2800 Mechelen |
Telefon: +32-1-563-26-00 |
Fax: + |
E-mail: info@biocartisgroupnv.be |
Biocartis Group NV engages in the development of personalized medicine for patients around the world. It also focuses on developing and commercializing oncology tests. The company was founded by Philippe Renaud, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium. |
Roger Moody | Chairman of Managing Board |
George Cardoza | Member of Executive Committee |
Piet Houwen | Member of Executive Committee |
Herman Verrelst | Chairman of Supervisory Board |
Bryan DeChairo | Member of Supervisory Board |
Christian Reinaudo | Member of Supervisory Board |
Christine Kuslich | Member of Supervisory Board |
Ann-Christine M. Sundell | Member of Supervisory Board |
Luc Gijsens | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer